Abbott Laboratories has withdrawn the obesity drug Sibutramine (Meridia) from the market in light of clinical trial data pointing to an increased risk for stroke and myocardial infarction, the US Food and Drug Administration (FDA) announced. The agency asked Abbott Laboratories to pull the drug from the market after it evaluated data from a […]